Ozon Pharmaceuticals is expanding its export potential—in 2025, the company reached agreements to export pharmaceutical products to Oman and Pakistan. Negotiations are ongoing and projects are being implemented with companies from the UAE, Algeria, Morocco, Jordan, Nicaragua, and Syria, the press service of the Russian group told GxP News, noting that the main interest from potential partners lies in oncology drugs and biotech products.
Additionally, last year Ozon Pharmaceuticals already supplied products under government contracts to Iraq and Yemen—both under current registrations and through special import permits.
In the commercial segment, Ozon Pharmaceuticals products were shipped to Iraq, Belarus, and Turkmenistan. In Turkmenistan, the group markets Skinoclear (azelaic acid) for the treatment of acne, rosacea, and hyperpigmentation—the only Russian drug with this active ingredient, available in two forms: gel and cream.
“The process of entering foreign markets involves time and financial costs associated with undergoing registration procedures according to local regulatory requirements and establishing supply chains. Nevertheless, Ozon Pharmaceuticals is purposefully developing such cooperation mechanisms. We see additional opportunities in the upcoming launch of the group’s high-tech products—from Ozon Medica and Mabscale,” noted Andrey Gorshkov, Director of Export and Brand Portfolio Management at Ozon Pharmaceuticals.